MariTime HF (Recruiting)
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Obesity and Heart Failure
- Medicine
- Meridebart Cafraglutide
- Population
- Heart failure
- Phase
- III
- Starting year
- 2024